After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18. Since then, the stock has traded choppily as the company prepares for its second-quarter earnings call, due out after the market closes on Monday, Aug. 5. However, HIMS' most recent dip on the charts has it flashing a bullish signal. According to a study from Schaeffer's Senior Quantitative Analyst Rocky White, HIMS is within one standard deviation o ...

YTD Price Comparison Key Valuation Metric Price-to-Sales Forward Twelve Months (F12M) Long-Term Investment Visibility Management believes that partnerships with leading medical institutions and experts within each of Hims & Hers' specialties enable it to provide access to customized clinical solutions that are designed with a focus on safety and efficacy. This allows providers on the company's platform to meet their patients' clinical needs at an individual level, targeting things like side effects and adhe ...

The market expects Hims & Hers Health, Inc. (HIMS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 5, 2024, might help the stock move higher if these key ...

For the full year, the earnings estimate of $0.20 per share represents a change of +281.82% from the year-ago number. Investors might want to bet on Hims & Hers Health, Inc. (HIMS) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sel ...

Based on the most recent data, HIMS has returned 155.8% so far this year. Meanwhile, the Medical sector has returned an average of 6.8% on a year-to-date basis. This shows that Hims & Hers Health, Inc. is outperforming its peers so far this year. In TransMedics' case, the consensus EPS estimate for the current year increased 701.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Another stock in the Medical sector, TransMedics (TMDX) , has outperformed the sector so far this year. ...

Sustainability Projected Earnings Growth 90.00% Hims & Hers: A Story of Growth and Profitability Hims & Hers Health, Inc. (HIMS) Price Chart for Friday, July, 19, 2024 The company's foray into weight loss treatments, including the highly sought-after GLP-1 injections, further exemplifies its ability to adapt to market trends and capitalize on emerging opportunities. While GLP-1 is not the sole driver of Hims & Hers' investment thesis, it showcases the company's agility in integrating popular medications int ...

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. The most recent trading session ended with Hims & Hers Health, Inc. (HIMS) standing at $23.11, reflecting a +1. ...

Price is just one factor to consider. For other businesses, macro conditions remain challenging, and this has been reflected in their stock prices. All that said, if you're looking for intriguing stocks to buy that are trading at relatively meager valuations, there are some companies that could be compelling long-term investments. Here are two to consider as you add to your buy list. Hims & Hers (HIMS 3.18%) operates a health and wellness platform that lets users access telehealth services, prescriptions, a ...

文章核心观点 - 公司提供数字化医疗保健服务,包括性健康、心理健康、减肥和皮肤护理等 [1] - 公司还提供直接面向消费者的治疗方案,如治疗勃起功能障碍和脱发 [1] - 分析师认为公司股价虽然最近有所下跌,但仍值得逐步建仓 [2] 公司业务概况 - 公司今年业绩表现出色,2月份财报超预期,5月份再次交出不错的季度成绩 [3] - 公司最近宣布开始提供仿制版GLP-1减肥药,价格低于原研药,因原研药供应短缺而受到欢迎 [3] - 分析师认为这一业务收入来源可能只是暂时的,未来公司可能会转向销售原研药,这可能会影响利润率 [4] - 但分析师认为即使没有这一业务,公司的基本面也依然不错 [5]

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy). One other Medical stock that has outperformed the sector so far this year is Novo Nordisk (NVO) . The stock is up 37.6% year-to-date. In contrast, Novo Nordisk falls under the Large ...